Acumen Pharmaceuticals, Inc. (ABOS) stock
Close on Nov 13, 2026Market cap $15.48MP/E –Yield –
Key statistics
Valuation at the latest close; fundamentals over fiscal , balances at Sep 30, 2026
Valuation
- Market cap
- $15.48M
- P/E ratio
- –
- Price to sales
- –
- Price to book
- 0.45
- Dividend yield
- –
- Free cash flow yield
- -568.24%
Fundamentals
- Net income
- -$103.96M
- EPS, diluted
- -$1.54
- Free cash flow
- -$87.95M
- Book value per share
- $0.48
- Diluted shares
- 72M
Trading
- Next earnings
- Mar 25, 2027 (estimated, before the open)
- Previous close
- $0.22
- Open
- $0.22
- Day's range
- $0.19 – $0.23
- Volume
- 2,783,800
- Average volume (20 days)
- 7,127,789
- Index membership
- Russell 2000 (since Jun 2026)
- Beta (5 years)
- 1.34
- 52-week range
- $0.19 – $3.60
- RSI (14 days)
- 21.4
- Volatility (1 year)
- 122.9%
- Relative volume
- 1.46×
- WACC
- 11.9%
Index membership is inferred from the holdings of funds that track each index (IWM), as reported to the SEC for Jun 30, 2026. Join dates come from quarterly fund reports since 2019, so they are accurate to the quarter.
Market cap history
Month-end market cap since 2021, using shares outstanding reported at the time
Total return vs. the S&P 500
Price change plus reinvested dividends, to the close on Nov 13, 2026. The S&P 500 is measured by the SPY fund.
| Period | ABOS | S&P 500 | Difference | ABOS per year | S&P 500 per year |
|---|---|---|---|---|---|
| 1 month | -88.2% | -3.0% | −85.2 pts | ||
| 3 months | -91.6% | -2.8% | −88.8 pts | ||
| Year to date | -89.9% | +11.5% | −101.3 pts | ||
| 1 year | -88.2% | +13.5% | −101.6 pts | ||
| 3 years | -89.5% | +77.7% | −167.2 pts | -52.8% | +21.1% |
| 5 years | -98.3% | +72.6% | −171.0 pts | -56.0% | +11.5% |
Seven years at a glance
Fiscal years 2019 to 2025 and trailing twelve months, USD
Operating income
Net income
EPS, diluted
Free cash flow
Press releases
Releases Acumen Pharmaceuticals filed with the SEC as exhibits to Form 8-K or 6-K
- Update
- Results
- Results
- Update
- Results
- Results
About Acumen Pharmaceuticals
Biological Products, (No Diagnostic Substances)
Acumen Pharmaceuticals is a clinical-stage biopharmaceutical company focused on developing targeted disease-modifying therapies for Alzheimer’s disease. Its lead product candidate, sabirnetug (ACU193), is a recombinant humanized monoclonal antibody designed to selectively bind and neutralize soluble amyloid-beta oligomers, which are neurotoxic assemblies implicated in synaptic dysfunction and neurodegeneration. In addition to sabirnetug, the company is advancing blood-brain barrier-penetrating enhanced brain delivery therapies for Alzheimer’s pathology. As a clinical-stage enterprise, its candidates target individuals diagnosed with early Alzheimer’s disease, encompassing those with mild cognitive impairment or mild dementia associated with amyloid pathology.
Company profile, executives and historyAcumen Pharmaceuticals stock: common questions
What is Acumen Pharmaceuticals's stock price?
ABOS closed at $0.21 on Nov 13, 2026, down 1.83% on the day. Over the past 52 weeks it traded between $0.19 and $3.60.
What is Acumen Pharmaceuticals's market cap?
Acumen Pharmaceuticals was worth $15.48M at the close on Nov 13, 2026: the share price times the diluted shares outstanding.
What is ABOS's P/E ratio?
Acumen Pharmaceuticals lost money over the twelve months to Sep 30, 2026 (diluted EPS -$1.54), so it has no meaningful P/E ratio.
Does Acumen Pharmaceuticals pay a dividend?
No. Acumen Pharmaceuticals has not paid a cash dividend over the last twelve months.
When does Acumen Pharmaceuticals report earnings next?
Acumen Pharmaceuticals is expected to report Q4 FY2026 results on Mar 25, 2027, before the open. The date is estimated from its past reporting pattern until the company confirms it.
How has ABOS stock performed over the past year?
Including dividends, ABOS returned -88.2% over the past year, against +13.5% for the S&P 500.
How many ABOS shares are sold short?
5M shares were sold short at the latest FINRA report, 12.89% of the float, or 1.0 days of average trading volume.
Who are Acumen Pharmaceuticals's competitors?
Companies most similar to Acumen Pharmaceuticals by business, industry and size include CGTX, ACOG, NMRA, ALEC, PASG.
See a number that looks wrong?